RxDoctor Payments Data

Gillian Wolff, MD

Urology · Cooperstown, NYNPI 1578883559

Payments from drug & device makers

$1,982in general payments, 2019–2025

Across 32 payments — averaging $61.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$929
  • Axonics, Inc.$396
  • Astellas Pharma US Inc$343
  • AbbVie$184
  • Sumitomo Pharma America, Inc.$61
  • Coloplast$46
  • plus $24 from 1 others

What the payments were for

  • Travel & lodging$91646%
  • Food & beverage$68334%
  • Education$38319%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)9$929
Axonics, Inc.5$396
Astellas Pharma US Inc4$343
AbbVie(2 entities)8$184
Sumitomo Pharma America, Inc.3$61
Coloplast2$46
Urovant Sciences Inc1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,982 in reported general payments places this provider in the 40th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$61,797
Medicare patients
316
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron178$182,306
MyrbetriqMirabegron163$149,623
Estradiol172$11,373
PremarinEstrogens, Conjugated21$9,100
Trospium Chloride53$4,115
Solifenacin Succinate47$3,422
Clobetasol Propionate28$1,316
Desmopressin Acetate13$869
NitrofurantoinNitrofurantoin Macrocrystal20$840
Tolterodine Tartrate ErTolterodine Tartrate14$839
Tamsulosin Hcl58$748
Oxybutynin Chloride15$343
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$299
Alfuzosin Hcl ErAlfuzosin Hcl13$299
Oxybutynin Chloride ErOxybutynin Chloride14$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$61$182,306178 claims
Astellas Pharma US IncMyrbetriq$343$149,623163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 952 urology providers in New York.

Other urology in Cooperstown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →